Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III international, randomised, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 150 mg of oral oseltamivir twice daily in the treatment of hospitalised adults and adolescents with influenza

Next Previous
X
Search
Trial Profile

A Phase III international, randomised, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 150 mg of oral oseltamivir twice daily in the treatment of hospitalised adults and adolescents with influenza

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oseltamivir (Primary) ; Zanamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

    • Most Recent Events

    • 19 Feb 2015 Status changed from recruiting to active, no longer recruiting as per UKCRN record.
    • 25 Feb 2012 Additinoal trial location (Wales) identified as reported by UKCRN.
    • 19 Jan 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top